Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KSI-301
Therapeutic Area: Ophthalmology Product Name: KSI-301
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
Kodiak Sciences has concluded recruitment in its DAZZLE pivotal study of KSI-301, Kodiak's anti-VEGF antibody biopolymer conjugate, in patients with neovascular (wet) age-related macular degeneration. Over 550 patients enrolled worldwide.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TP-03
Therapeutic Area: Ophthalmology Product Name: TP-03
Highest Development Status: Phase II/ Phase III Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2020
Details:
The company announced compelling results from its Phase 2a Mars and Phase 2b Jupiter trials for TP-03. In both trials it was observed that the use of TP-03 for 4 weeks was well-tolerated and showed compelling efficacy in the treatment of Demodex blepharitis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KSI-301
Therapeutic Area: Ophthalmology Product Name: KSI-301
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2020
Details:
New data from the ongoing Phase 1b study of KSI-301, its novel anti-VEGF antibody biopolymer conjugate, will be presented at the upcoming American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
